Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
OLANZAPINE
Neurology & Sedation · Neurology & Sedation · Level 3
|
QUETIAPINE
Neurology & Sedation · Neurology & Sedation · Level 3
|
|---|---|---|
| Mechanism of action | D2 receptor antagonism, 5HT-R antagonism, H1-R/M-R/alpha1-R antagonism |
D2<5-HT2a and H1-R antagonism |
| Physiological effects | CVS: Orthostatic hypotension CNS: Somnolence. Lowers seizure threshold GIT: Dysphagia Metabolic/Other: Hyperglycaemia and increased risk of developing diabetes |
sedating |
| Absorption | Good oral absorption |
Good oral absorption |
| Protein binding | 98% |
Protein bound |
| Metabolism | Hepatic metabolism. Smoking induces the CYP1A2 metabolism of olanzapine |
Active metabolite norquetiapine which has anticholinergic effects |
| Half-life | Terminal T1/2 is 33 hours |
Elimination t1/2 is 7 hours, active metabolite elimination T1/2 is 12 hours |
| Class Group | Second Generation Antipsychotics/Atypical (D2-Antagonism/5-HT2a) |
Second Generation Antipsychotics/Atypical (D2-Antagonism/5-HT2a) |
| Indications Uses | - Psychosis |
1. Psychosis |
| Introduction | — | Atypical antipsychotic |
| Legacy Cicm Level | Level 3 |
Level 3 |
| Presentation | Oral wafer, tablet |
IR and SR tablets |